Qualify For a Study or Trial

The biggest obstacle in getting a celiac drug to market is recruiting enough patients to participate in clinical trials. Your participation is critical.

Take charge of your celiac disease to make better treatments and, one day, a cure for celiac disease a reality. Gain a better understanding of your celiac disease and how to manage it and potentially benefit from new medications or therapies that can improve your symptoms and your quality of life. See if you may qualify for a study or trial today!

 

Current Studies & Trials

Michigan & Utah

TEV-CeD Study

Now enrolling adults with celiac disease to participate in a research study investigating TEV-53408 for the treatment of celiac disease.   

TEV-53408 is an investigational antibody designed to block interleukin-15 with the goal of preventing intestinal damage and symptoms that occur when people with celiac disease ingest gluten.      

Compensation for time and travel may be available.  

 Requirements:  

  • 18-70 years old  
  • Biopsy-confirmed celiac disease  
  • On a gluten-free diet 

 Learn more at tevstudy.celiac.org.

See If You Qualify

U.S. Multi-Site

ILLUMINATE-062 Study

The ILLUMINATE-062 Study is a phase 2 clinical research study evaluating the safety and effectiveness of an investigational drug designed to break down gluten in the stomach and improve control of celiac disease for people on a gluten-free diet. If you periodically experience celiac-related gastrointestinal symptoms, despite your best efforts to follow a gluten-free diet, this study may be a good fit for you.

In order to qualify, one must:

  • Be 18 years old or older
  • Have biopsy-confirmed celiac disease
  • Have been on a gluten-free diet for at least the past 12 months

Some study visits can be completed at home, and all study-related care will be provided at no cost. Participants may be compensated for time + travel.

To learn more, please visit: illuminatecd-cdf2.com.  

See If You Qualify

U.S. Multi-Site

SynCeD Study

This study is a phase 2a clinical trial testing the safety, tolerability, and efficacy of the investigational medication KAN-101. 

KAN-101 targets the immune cells that drive celiac disease and leaves the otherwise healthy components of the immune system intact. KAN-101 acts by re-educating T cells, or tolerizing them, so they do not respond to gluten antigens.  

This trial may be an option for you if you: 

  • Are 18-70 years old 
  • Have biopsy-confirmed celiac disease 
  • Currently follow a gluten-free diet 

Learn more at Anokion.com/SynCeD.

See If You Qualify

It is important for patients to fully understand the potential risks and benefits of participating in a study or clinical trial and to discuss their options with their healthcare provider before making a decision. However, for many celiac patients, participation in a study or clinical trial can be a valuable and rewarding experience.